Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956247 | 1.00 | TDP1 (0.44) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL22028677 | 0.76 | TDP1 (0.44) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL3663843 | 0.76 | ALDH1A1 (0.39) | TDP1ALDH1A1TSHRKIF11 | |
| SCHEMBL243121 | 0.73 | CA2 (0.48) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL30050643 | 0.73 | CYP2A6 (0.31) | — | |
| SCHEMBL409191 | 0.73 | CYP2A6 (0.31) | — | |
| SCHEMBL580584 | 0.73 | ALDH1A1 (0.63) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL29355273 | 0.73 | ALDH1A1 (0.63) | TDP1ALDH1A1TSHRCA2GABRA1 | |
| SCHEMBL8531624 | 0.70 | — | — | |
| SCHEMBL8225509 | 0.70 | PTGS1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301184-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-10 | — | — | US | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20230128259-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2018-08-07 | — | — | US | disclosed |
| US-9938292-B2 | Quinoline derivatives as SMO inhibitors | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-11-23 | — | — | US | disclosed |
| US-20110172280-A1 | Substituted Benzimidazoles | CONCERT PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7915271-B2 | 1,3-oxazolidin-2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | AMGEN INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20090137548-A1 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-05-28 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | TDP1 4089/4885ALDH1A1 314/4885TSHR 1451/4885 |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | TDP1 2168/4885ALDH1A1 3152/4885TSHR 3447/4885 |
| US-20110060011-A1 | OXAZOLE COMPOUNDS COMPOSITIONS AND METHODS OF USE | OXA1L, CYP11B2, CYP3A7 | TDP1 2517/4885ALDH1A1 132/4885TSHR 4147/4885 |
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | TDP1 1706/4885ALDH1A1 665/4885TSHR 1061/4885 |
| US-20230248753-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | TDP1 2455/4885ALDH1A1 3784/4885TSHR 4572/4885 |
| US-10040759-B2 | Substituted azetidinyl compounds as GlyT1 inhibitors | GLRA1, AGXT, B4GALT1 | TDP1 906/4885ALDH1A1 308/4885TSHR 1724/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | TDP1 3959/4885ALDH1A1 303/4885TSHR 1169/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | TDP1 2573/4885ALDH1A1 1326/4885TSHR 2017/4885 |
| US-20230301184-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS THEREOF | OCIAD1, OCIAD2, OSTC | TDP1 3544/4885ALDH1A1 641/4885TSHR 3760/4885 |
| US-20170334846-A1 | SUBSTITUTED AZETIDINYL COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, AGXT, B4GALT1 | TDP1 906/4885ALDH1A1 308/4885TSHR 1724/4885 |
| US-20230128259-A1 | COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | L1CAM, CRY1, CRY2 | TDP1 2640/4885ALDH1A1 22/4885TSHR 3181/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | TDP1 3571/4885ALDH1A1 3411/4885TSHR 4454/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | TDP1 4092/4885ALDH1A1 1138/4885TSHR 3755/4885 |
| US-20110172280-A1 | Substituted Benzimidazoles | GABRA5, GABRB1, GABRA4 | TDP1 3396/4885ALDH1A1 151/4885TSHR 1444/4885 |
| US-20090137548-A1 | 1,3-Oxazolidin-2-One Derivatives Useful as Cetp Inhibitors | CETP, MTTP, APOB | TDP1 224/4885ALDH1A1 1605/4885TSHR 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.